Alnylam price target raised to $288 from $253 at UBS

UBS raised the firm’s price target on Alnylam to $288 from $253 and keeps a Buy rating on the shares after hosting meetings with management. The analyst left the meetings with increased conviction in Alnylam’s growth. The ATTR-CM commercial opportunity for vutrisiran and the company’s longer term platform capabilities beyond the liver could be underappreciated, and have potential to have key updates over the next 12-18 months, the analyst tells investors in a research note. The firm thinks the HELIOS-B data is transformational in terms of unlocking a significant opportunity in ATTR-CM.